References
- Camp KM, Parisi MA, Acosta PB, Berry GT, Bilder DA, Blau N, Bodamer OA, Brosco JP, Brown CS, Burlina AB, et al. Phenylketonuria scientific review conference: state of the science and future research needs. Mol Genet Metab. 2014;112(2):87–122. doi:https://doi.org/10.1016/j.ymgme.2014.02.013.
- Jervis GA. Phenylpyruvic oligophrenia deficiency of phenylalanine-oxidizing system. Proc Soc Exp Biol Med. 1953;82(3):514–5.
- Scriver CR. The PAH gene, phenylketonuria, and a paradigm shift. Hum Mutat. 2007;28(9):831–45. doi:https://doi.org/10.1002/humu.20526.
- Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376(9750):1417–27. doi:https://doi.org/10.1016/S0140-6736(10)60961-0.
- Elsas LJ, Greto J, Wierenga A. The effect of blood phenylalanine concentration on Kuvan response in phenylketonuria. Mol Genet Metab. 2011;102(4):407–12. doi:https://doi.org/10.1016/j.ymgme.2010.12.003.
- Demirkol M, Giżewska M, Giovannini M, Walter J. Follow up of phenylketonuria patients. Mol Genet Metab. 2011;104:S31–S9. doi:https://doi.org/10.1016/j.ymgme.2011.08.005.
- Al Hafid N, Christodoulou J. Phenylketonuria: a review of current and future treatments. Transl Pediatr. 2015;4(4):304–17. doi:https://doi.org/10.3978/j.issn.2224-4336.2015.10.07.
- van Vliet D, Bruinenberg VM, Mazzola PN, van Faassen MH, de Blaauw P, Pascucci T, Puglisi-Allegra S, Kema IP, Heiner-Fokkema MR, van der Zee EA, et al. Therapeutic brain modulation with targeted large neutral amino acid supplements in the Pah-enu2 phenylketonuria mouse model. Am J Clin Nutr. 2016;104(5):1292–300. doi:https://doi.org/10.3945/ajcn.116.135996.
- Gonzalez MJ, Gutierrez AP, Gassio R, Fuste ME, Vilaseca MA, Campistol J. Neurological complications and behavioral problems in patients with phenylketonuria in a follow-up unit. Mol Genet Metab. 2011;104 Suppl:S73–S9. doi:https://doi.org/10.1016/j.ymgme.2011.07.015.
- MacDonald A, Rocha JC, van Rijn M, Feillet F. Nutrition in phenylketonuria. Mol Genet Metab. 2011;104(Suppl):S10–S8. doi:https://doi.org/10.1016/j.ymgme.2011.08.023.
- van Spronsen FJ, van Wegberg AM, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, Burlina A, Campistol J, Feillet F, Giżewska M, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endo. 2017;5(9):743–56. doi:https://doi.org/10.1016/S2213-8587(16)30320-5.
- Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, Mitchell J, Smith WE, Thompson BH, Berry SA, American College of Medical Genetics and Genomics Therapeutics Committee, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16(2):188–200. doi:https://doi.org/10.1038/gim.2013.157.
- Imperlini E, Orru S, Corbo C, Daniele A, Salvatore F. Altered brain protein expression profiles are associated with molecular neurological dysfunction in the PKU mouse model. J Neurochem. 2014;129(6):1002–12. doi:https://doi.org/10.1111/jnc.12683.
- Smith QR. Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr. 2000;130(4S Suppl):1016S–22S. doi:https://doi.org/10.1093/jn/130.4.1016S.
- van Spronsen FJ, Hoeksma M, Reijngoud DJ. Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause? J Inherit Metab Dis. 2009;32(1):46–51. doi:https://doi.org/10.1007/s10545-008-0946-2.
- Pratt OE. A new approach to the treatment of phenylketonuria. J Ment Defic Res. 1980;24(3):203–17. doi:https://doi.org/10.1111/j.1365-2788.1980.tb00074.x.
- Huemer M, Simma B, Mayr D, Möslinger D, Mühl A, Schmid I, Ulmer H, Bodamer OA. Free asymmetric dimethylarginine (ADMA) is low in children and adolescents with classical phenylketonuria (PKU). J Inherit Metab Dis. 2012;35(5):817–21. doi:https://doi.org/10.1007/s10545-011-9448-8.
- Kumru B, Kaplan DS, Ozturk Hismi B, Celik H. Effect of blood phenylalanine levels on oxidative stress in classical phenylketonuric patients. Cell Mol Neurobiol. 2018;38(5):1033–8. doi:https://doi.org/10.1007/s10571-017-0573-2.
- Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104(21):2569–75. doi:https://doi.org/10.1161/hc4601.098514.